
Sign up to save your podcasts
Or


Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Tune in as we chat with Dr. Yasmin Karimi from the University of Michigan about the latest breakthroughs in treatment, including combination therapies, CAR T-cell therapy and bispecific antibodies. Discover how these innovations are offering new hope and pathways to cures for patients.
Mentioned on this episode:
Additional LLS Support Resources:
Support for this episode provided by Genmab US, Inc.
The post Emerging Therapies and Hope: Diffuse Large B-cell Lymphoma first appeared on The Bloodline with Blood Cancer United Podcast.
By Blood Cancer United4.9
4646 ratings
Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Tune in as we chat with Dr. Yasmin Karimi from the University of Michigan about the latest breakthroughs in treatment, including combination therapies, CAR T-cell therapy and bispecific antibodies. Discover how these innovations are offering new hope and pathways to cures for patients.
Mentioned on this episode:
Additional LLS Support Resources:
Support for this episode provided by Genmab US, Inc.
The post Emerging Therapies and Hope: Diffuse Large B-cell Lymphoma first appeared on The Bloodline with Blood Cancer United Podcast.

25,859 Listeners

14,459 Listeners

37,020 Listeners

12,137 Listeners

87,332 Listeners

112,482 Listeners

206 Listeners

5,106 Listeners

12 Listeners

4,781 Listeners

14,309 Listeners

6,562 Listeners

8,190 Listeners

6,421 Listeners

41,510 Listeners